Acadian Asset Management LLC Buys Shares of 1,251 Repligen Co. (NASDAQ:RGEN)

Acadian Asset Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,251 shares of the biotechnology company’s stock, valued at approximately $157,000.

Several other institutional investors and hedge funds have also modified their holdings of RGEN. Principal Securities Inc. bought a new position in shares of Repligen during the 4th quarter valued at approximately $48,000. Dimensional Fund Advisors LP boosted its position in shares of Repligen by 5.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 301,968 shares of the biotechnology company’s stock worth $54,306,000 after purchasing an additional 16,430 shares during the period. Quadrant Capital Group LLC increased its stake in shares of Repligen by 15.1% in the fourth quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 85 shares in the last quarter. Norges Bank bought a new stake in shares of Repligen during the 4th quarter valued at $48,208,000. Finally, Corient Private Wealth LLC raised its position in shares of Repligen by 28.0% during the 4th quarter. Corient Private Wealth LLC now owns 7,011 shares of the biotechnology company’s stock valued at $1,261,000 after purchasing an additional 1,532 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Guggenheim started coverage on Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $190.00 target price on shares of Repligen in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $188.38.

Repligen Trading Down 1.9 %

RGEN opened at $142.97 on Friday. The stock has a 50-day moving average of $147.30 and a 200 day moving average of $155.51. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The firm has a market cap of $8.01 billion, a P/E ratio of 571.90, a P/E/G ratio of 4.14 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS. As a group, research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.